# Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

> **NCT02846142** · PHASE1 · COMPLETED · sponsor: **Proteostasis Therapeutics, Inc.** · enrollment: 94 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** PTI-428
- **OTHER:** Placebo
- **DRUG:** ethinyl estradiol and levonorgestrel

## Key facts

- **NCT ID:** NCT02846142
- **Lead sponsor:** Proteostasis Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2018-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02846142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02846142, "Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02846142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*